Skip to content

A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors

A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06831838
Enrollment
116
Registered
2025-02-18
Start date
2025-02-06
Completion date
2026-12-31
Last updated
2026-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

The purpose of this research is to evaluate the effectiveness of a multidisciplinary pain management program for AIMSS in reducing pain, subjective cognitive complaints, psychological distress, and impaired functional status resulting in improved adherence to Aromatase Inhibitor medications compared to usual care. We want to identify predictors of improvement in pain, functional status, subjective cognition and mood following participation in the program.

Interventions

BEHAVIORALCognitive Behavioral Therapy based Pain Management Program

Subjects will participate in a two-day structured class that will focus on Cognitive-Behavioral skills and strategies to improve pain control, fatigue, sleep disturbance, cognitive symptoms, and stress while educating patients on the efficacy of Aromatase Inhibitors in prolonging cancer-free survival with the goal of eliminating non-adherence.

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* At least 18 years old * ECOG ≤ 2 * Stage 0-III HR+ breast cancer in need of strategies to reduce symptoms and improve quality of life

Exclusion criteria

• Less than 18 years of age. \- Stage 4 HR+ breast cancer

Design outcomes

Primary

MeasureTime frameDescription
Adherence to Aromatase Inhibitors (AIs)Baseline, 3 months, 6 monthsAdherence to Aromatase Inhibitors (AIs) medications will be collected as a self-reported question asking the patients if they have taken their medications as prescribed during the past month (yes vs. no).
AIMSS Follow-up QuestionnaireBaseline, 3 months, 6 monthsSubjects will complete the study follow-up questionnaire with study staff to indicate whether they are adhering to medications and to report symptoms.

Secondary

MeasureTime frameDescription
Brief Pain InventoryBaseline, 3 months, 6 monthsThe Brief Pain Inventory (BPI) allows participants to rate the severity of their pain and the degree to which their pain interferes with common dimensions of feeling and function. Possible scores range from 0 to 10 with higher scores indicating a worse outcome/more severe pain and interference.
Center for Epidemiologic Studies of Depression - Revised QuestionnaireBaseline, 3 months, 6 monthsThe Center for Epidemiologic Studies Depression Scale-Revised (CESD-R) is a 20-item, self-reported questionnaire, that measures symptoms of depression. Each item is rated on a Likert scale, with 0 = 'Not at all or less than one day", and 3 = "Nearly every day for 2 weeks". Scores range from 0-60, with a score of 16 or higher indicating a risk of clinical depression.
Pain Catastrophizing ScaleBaseline, 3 months, 6 monthshe Pain Catastrophizing Scale (PCS) is a 13-item self-report measure designed to assess catastrophic thinking related to pain. Items are rated on 5-point Likert scale, with 0 = "Not at all" and 4 = "All the time" Higher score indicates higher level of catastrophizing.
Brief Resilience ScaleBaseline, 3 months, 6 monthsThe Brief Resilience Scale is a 6 item, self-reported questionnaire, measuring how well a person recovers from stress. Each item is rated on a Likert scale, with 1 = "Strongly Disagree" and 5 = "Strongly Agree". The Brief Resilience Scale is scored by adding the value of all responses and dividing by 6. Higher scores indicate higher resilience to stress.
Social Support SurveyBaseline, 3 months, 6 monthsThe Social Support Survey is a 4 item, self-reported questionnaire, assessing the availability of support. Items are rated on a 4 point Likert scale, with 0 = "None of the time" and 4 = "All of the time". Higher scores indicate a greater level of support.
World Health Organization (WHO) Disability Assessment ScheduleBaseline, 3 months, 6 monthsThe WHO Disability Assessment Schedule is a 36-item, self-reported questionnaire, assessing health and disability. The questionnaire cover 6 domains: cognition, mobility, self-care, getting along, life activities, and participation. Each item is rated on a 5 point Likert scale, with 0 = "None" and 4 = "Extreme or Cannot do". Higher scores indicate greater disability.
State-Trait InventoryBaseline, 3 months, 6 monthsThe State-Trait Inventory is a self-reported questionnaire, used to assess anxiety. Participants respond to 40 questions about how they are currently feeling on a scale of 1 "Not at all" to 4 "Very much so". Total possible scores range from 40 to 160. Higher scores indicate higher anxiety (a worse outcome) and lower scores indicate less anxiety (a better outcome).
Cognitive Functioning Index (CFI)Baseline, 3 months, 6 monthsThe Cognitive Function Index (CFI) is a 14-item, self-reported questionnaire, used to assess cognitive status. Total scores range from 0-29, with higher scores indicating an increased perception about cognitive difficulties.

Countries

United States

Contacts

CONTACTAlejandra Cuartas-Abril, M.S.
Cuartas-Abril.Alejandra@mayo.edu904-956-8885
PRINCIPAL_INVESTIGATORBarbara Bruce, Ph.D., LP

Mayo Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 5, 2026